CN104585767B - A kind of health products and preparation technology for reducing blood fat - Google Patents
A kind of health products and preparation technology for reducing blood fat Download PDFInfo
- Publication number
- CN104585767B CN104585767B CN201510063794.0A CN201510063794A CN104585767B CN 104585767 B CN104585767 B CN 104585767B CN 201510063794 A CN201510063794 A CN 201510063794A CN 104585767 B CN104585767 B CN 104585767B
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- red yeast
- yeast rice
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000036541 health Effects 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000008280 blood Substances 0.000 title abstract description 43
- 210000004369 blood Anatomy 0.000 title abstract description 43
- 229940026314 red yeast rice Drugs 0.000 claims abstract description 33
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 20
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 20
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 19
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 19
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 19
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 239000000843 powder Substances 0.000 claims description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- 239000003814 drug Substances 0.000 claims description 30
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 20
- 241000218628 Ginkgo Species 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 235000012000 cholesterol Nutrition 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 230000005855 radiation Effects 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 244000018633 Prunus armeniaca Species 0.000 claims 1
- 235000009827 Prunus armeniaca Nutrition 0.000 claims 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims 1
- 229910052709 silver Inorganic materials 0.000 claims 1
- 239000004332 silver Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 22
- 210000004185 liver Anatomy 0.000 abstract description 18
- 210000000952 spleen Anatomy 0.000 abstract description 16
- 210000004204 blood vessel Anatomy 0.000 abstract description 14
- 150000002632 lipids Chemical class 0.000 abstract description 11
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 10
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 9
- 230000017531 blood circulation Effects 0.000 abstract description 9
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 8
- 239000000463 material Substances 0.000 abstract description 8
- 231100000216 vascular lesion Toxicity 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 210000001367 artery Anatomy 0.000 abstract description 4
- 230000008439 repair process Effects 0.000 abstract description 4
- 230000002537 thrombolytic effect Effects 0.000 abstract description 4
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract description 3
- 238000000034 method Methods 0.000 abstract description 3
- 230000000977 initiatory effect Effects 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 210000003462 vein Anatomy 0.000 abstract description 2
- 244000194101 Ginkgo biloba Species 0.000 abstract 1
- 239000000047 product Substances 0.000 description 31
- 241000700159 Rattus Species 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000002792 vascular Effects 0.000 description 10
- 239000002775 capsule Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 206010008190 Cerebrovascular accident Diseases 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 7
- 208000006011 Stroke Diseases 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 244000241838 Lycium barbarum Species 0.000 description 4
- 235000015459 Lycium barbarum Nutrition 0.000 description 4
- 210000003710 cerebral cortex Anatomy 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 240000001008 Dimocarpus longan Species 0.000 description 3
- 235000000235 Euphoria longan Nutrition 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011812 mixed powder Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- QDGIAPPCJRFVEK-UHFFFAOYSA-N (1-methylpiperidin-4-yl) 2,2-bis(4-chlorophenoxy)acetate Chemical compound C1CN(C)CCC1OC(=O)C(OC=1C=CC(Cl)=CC=1)OC1=CC=C(Cl)C=C1 QDGIAPPCJRFVEK-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000221377 Auricularia Species 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000165940 Houjia Species 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960002174 ciprofibrate Drugs 0.000 description 1
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229950009619 lifibrate Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention provides a kind of health products and preparation technology for reducing blood fat.The health products of the present invention can be used in treating angiocardiopathy.Product of the invention takes into account " release vasopasm, thrombolysis row fat, repair damaged blood vessels " three aspects, synchronously sets about, thinks that " steady network work arteries and veins, dissolving stasis row is turbid, invigorates blood circulation raw new " is main idea, the vascular lesion that can fundamentally solve initiation cardiovascular and cerebrovascular diseases.The present invention is from red yeast rice, pseudo-ginseng, Folium Apocyni Veneti, ginkgo leaf, the root of kudzu vine as raw material, each material combination, hyperlipemia of hitting is insufficiency of the spleen and lose strong fortune, liver depression knot and it is hot, the uncomfortable interpretation of the cause, onset and process of an illness of qi depression to blood stasis, spleen liver, invigorating the spleen for eliminating dampness, promoting blood circulation and removing blood stasis, clearing liver are played altogether, mends the effect of spleen and liver, reach the healthcare function of auxiliary reducing blood lipid.Also, the present invention can reach reparation blood vessel while reducing blood lipid, the effect of reducing incidence of cardiovascular disease.
Description
Technical field
The present invention relates to traditional Chinese medicine health care product, in particular to a kind of health products and preparation technology for reducing blood fat.
Background technology
Hyperlipidemia is due to that fat metabolism or operating exception make cholesterol, triglycerides and (or) low-density lipoprotein mistake
A kind of illness that high and (or) HDL is too low and triggers.Hyperlipidemia early stage majority does not have clinical manifestation, to body
Infringement be concealment, gradually, progressive and systemic.Its direct infringement is to strengthen systemic atherosclerosis, and whole body
Vitals by artery blood supply, oxygen supply, once atheromatous plaque block artery, will result in serious consequence.Largely grind
To study carefully and show, atherosclerosis caused by hyperlipidemia is the main reason for causing coronary heart disease, hypertension and cranial vascular disease,
It is a hazards for promoting diabetes, can also result in the generation of the diseases such as fatty liver, hepatic sclerosis.
Western medicine lipid-lowering medicine mainly has two major classes at present, to reduce first-elected statin based on T-CHOL and low-density lipoprotein
Class, including Lovastatin, Simvastatin, Pravastatin etc.；Reduce triglycerides be main person using fibrates as representative, such as fenofibrate
Spy, Lifibrate, ciprofibrate and Clofibrate etc..But they have very serious side effect：Such as stomachache, diarrhoea, abdominal distension, dislike
The heart, transaminase rise, has a stuffy nose, and headache, pharyngalgia, influenza syndrome, nasosinusitis, pectoralgia, insomnia, apocleisis, hepatic and renal function is abnormal, flesh
Meat pain etc..The effect for reducing fat of Western medicine is by blocking Fatty synthesis, or reduces fat to reach.Generated during this
Largely, it is more harmful than fat, it more difficult to decompose, it more difficult to the human toxin of excretion, be really to lose more than gain.More important is,
Western medicine reducing blood lipid does not solve human body production hyperliposis really, using the real cause of disease of fatty deficiency, causes some patients
It need to all the life take medicine, endure the hardship of huge side effect murder by poisoning all the life；No matter some patients can not be dropped any more with which kind of lipid-lowering medicine, blood fat
Come, after some patient's medications, blood fat does not drop to soar on the contrary.Therefore, using Western medicine come reduce blood fat can be brought to human body it is many
Harm and side effect.
And in actual life, hypertension and high fat of blood are often existing together.The harm of high blood pressure burst is
High mortality, high disability rate.After high blood pressure develops into certain phase, " sudden heart infarction and sudden apoplexy (brain easily occurs
Stalk or cerebral hemorrhage) ".Heart infarction, apoplexy, such as rescue not in time, can all cause death.Even if apoplexy rescue is timely, also can different journeys
Apoplexy sequelae must be fallen by spending.
The vascular lesion of diabetes is one of common diabetic complication, and this is also the master for causing diabetic dead
One of reason is wanted, most common vascular lesion has cardiovascular pathological changes, cerebrovascular disease, the capilary of kidney, retina and skin
Lesion etc..Vascular complication caused by vascular complication, diabetes caused by heart disease, apoplexy sequelae, high blood pressure, these
The co-morbid reason of disease is exactly vascular lesion.The cardiovascular and cerebrovascular diseases triggered by vascular lesion, it has also become have a strong impact on the mankind
Health, cause most one of dangerous diseases of high mortality, high disability rate
Therefore, in the market needs one kind to have no toxic side effect, and can effectively reduce human body blood fat and treat angiocardiopathy
Health products or medicine.
The content of the invention
The consultant YAN Zheng-hua professor that applicant company is engaged thinks：Cause the vascular lesion of cardiovascular and cerebrovascular diseases, mainly from
Two aspects start, " first, blood vessel spasm itself；Second, internal blood vessel there are blood lipid deposition ", the two influences each other,
Caused result is exactly that " blood vessel elasticity declines, and hardening aggravates；Vascular wall is impaired to be aggravated, thinning；Intravascular Thrombus is formed ".
So when blood vessel elasticity deficiency, when vascular wall is thinning, it is easy for causing rupture of blood vessel in brain, we term it brain to overflow
Blood is hemorrhagic cerebral apoplexy；And when blood vessel elasticity deficiency, when thrombus gradually forms, cerebral infarction or heart infarction can be caused again.
Vascular lipid deposits, and is on the one hand influenceed by high fat of blood, on the other hand also relevant with vasopasm；Vasopasm,
Mainly caused by cerebral cortex layer excitement, the influence such as the excitement of cerebral cortex layer is stressed again, mood.So job and life stress
Greatly, love is angry, mood is not smooth, requires that oneself higher, eager to do well in everything perfectionist is more prone to the excitement of cerebral cortex layer；
Eat it is very good grow very much greasy, the few people's blood fat of activity is easy for height.Certainly, this two classes crowd, also it is easiest to that cardiovascular and cerebrovascular occurs
Disease.
Why many cardiovascular and cerebrovascular patients now, control bad long, does not still catch in the treatment and causes angiosis
Become it is basic, such as the medicine taken, or be directly act on blood vessel expander (directly expansion blood vessel with by conditioning greatly
Cerebral cortex layer is come to release vasopasm be two different concepts), otherwise it is lipid lowering agent or blood-activating formula.
So many cardiovascular and cerebrovascular patients, have three kinds of universal situations：First, by taking lipid-lowering medicine, blood fat drop
Get off, but cardiovascular and cerebrovascular diseases are also present；Second, blood fat is not high, within normal range (NR), but there are cardiovascular and cerebrovascular diseases；
Third, the medicine that largely can directly expand blood vessel has been taken, but effect is worse and worse, or even Secondary cases mistake is generated to the end
Effect.
Therefore, in view of the above-mentioned problems, the present invention uses for reference the rules for the treatment of of the Traditional Chinese Medicine theory to hyperlipemia, combine again modern
Pharmacological experiment is studied, and is primary raw material from red yeast rice, pseudo-ginseng, Folium Apocyni Veneti, ginkgo leaf, the root of kudzu vine, is added through modern crafts science
Work have developed the square joyful capsule of board in health food side.The present invention is main using red yeast rice, pseudo-ginseng, Folium Apocyni Veneti, ginkgo leaf, the root of kudzu vine
Raw material, mutual compatibility between each raw material, no incompatibility, the health care work(of significant auxiliary reducing blood lipid can be played on formula and dosage
Can, and can fundamentally solve the crux of cardiovascular disease.
Closed individually below from red yeast rice, pseudo-ginseng, Folium Apocyni Veneti, ginkgo leaf, the mechanism of action of the root of kudzu vine and efficacy effect and compatibility
It is to illustrate the scientific rationality of this product screening raw material.Red yeast rice is sweet, warm-natured, Return liver, spleen, large intestine channel, has invigorating the spleen for eliminating dampness, work
The effect of blood stagnation resolvation.Pseudo-ginseng is sweet, slight bitter, temperature.Return liver, stomach.Its main function is the row stasis of blood of invigorating blood circulation, promote blood circulation.Folium Apocyni Veneti
It is cool, sweet, bitter, return liver warp.With clearing liver fire, it is calming the liver to stop the wind the effect of, be traditional calming liver and clearing heat simply Chinese medicine.Ginkgo leaf
It is sweet, bitter, puckery, mild-natured, the thoughts of returning home, lung channel, the traditional Chinese medical science think its have it is promoting blood circulation and removing blood stasis, change turbid lipid-loweringing, astringe the lung and other effects.Root of kudzu vine taste
It is sweet, pungent, cool in nature, returns spleen, stomach.Motherland's medical science thinks root of kudzu vine rising Yang, promotes the production of body fluid, invigorates blood circulation, dredging collateral, and carries Bu Jinfa with liter and be good for
Spleen.More than each material combination, hyperlipemia of hitting is insufficiency of the spleen and loses strong fortune, liver depression knot and hot, the uncomfortable disease of qi depression to blood stasis, spleen liver
Machine, invigorating the spleen for eliminating dampness, promoting blood circulation and removing blood stasis, clearing liver are played altogether, mends the effect of spleen and liver, reaches the healthcare function of auxiliary reducing blood lipid.It is a large amount of existing
Significant effect for reducing blood fat is respectively provided with for each raw material in the pharmacological research side of also demonstrating that, and the present invention fundamentally solves painstaking effort
The cause of disease of pipe disease, it can be used for treating heart disease crowd, hypertension and vascular complication crowd, apoplexy sequelae crowd, glycosuria
Disease and vascular complication crowd, the cardiovascular disease of people with hyperlipidemia.(used in the present invention was originally conventional commercial Chinese medicine
Material)
Specifically, on the one hand, the present invention provides a kind of preparation technology for the health products for reducing blood fat, it is characterised in that
It comprises the following steps：
1) pseudo-ginseng 150-320 parts, Folium Apocyni Veneti 130-270 parts, ginkgo leaf 600-850 parts, root of kudzu vine 650-, are prepared respectively
900 parts, by weight；
2), the Chinese medicine prepared in step 1) is added in extractor, and addition ethanol is molten in the extractor
Liquid；
3), in the extractor is carried out to the Chinese medicine prepared the alcohol extracting scheduled time；
4), the mixture in the extractor is filtered, discards the dregs of a decoction, obtains alcohol extract；
5), the alcohol extract be concentrated under reduced pressure and obtain corresponding thick medicinal extract, and reclaim ethanol；
6), the thick medicinal extract is dried, obtains dry extract；
7), the dry extract is crushed and sieved, obtains extract extract powder；
8) red yeast rice 85-170 parts, are prepared, and the red yeast rice to being prepared carries out radiation sterilizing；
9), the red yeast rice through sterilization processing is crushed, obtains red yeast rice powder；
10), the red yeast rice powder is well mixed with the extract extract powder, obtains the medicinal powder of the health product；
11) quantitative separating, is carried out to the medicinal powder.
Drying process preferably uses vacuum drying mode in the present invention, of course it is not excluded other drying sides can also be used
Formula.Water used herein can be the drinking water for meeting national standard, or purified water.
Further, the preparation technology, which is additionally included in the dry extract, adds starch 8-25 parts and magnesium stearate
1.8-3.5 part.
Further, the dosage of the red yeast rice be 135 parts, 250 parts of pseudo-ginseng, 200 parts of Folium Apocyni Veneti, 750 parts of ginkgo leaf, Pueraria lobota
750 parts of root.
Further, the red yeast rice warp60Co radiation sterilizings, also, when being concentrated to alcohol extract, used concentration
Condition is：55~65 DEG C of temperature, vacuum 0.08MPa；And the alcohol extract is concentrated into relative density as 1.20~1.25.
Further, described also to include enclosing the mixture in capsule, every capsule adds medicine described in 0.4-0.5g
Powder.
On the other hand, the present invention provides a kind of health products for reducing blood fat, it is characterised in that three are included in the health products
Seven 150-320 parts, Folium Apocyni Veneti 130-270 parts, ginkgo leaf 600-850 parts, root of kudzu vine 650-900 parts, or pseudo-ginseng 150-320
Part, Folium Apocyni Veneti 130-270 parts, ginkgo leaf 600-850 parts, the extract of root of kudzu vine 650-900 parts, and wrapped in the health products
The parts of 85-170 containing red yeast rice.
Further, the health products include pseudo-ginseng, Folium Apocyni Veneti, ginkgo leaf, alcohol extract institute's shape after drying of the root of kudzu vine
Into the powder of dry extract and the powder of red yeast rice.
Further, the dosage of raw material each by mass is 135 parts of red yeast rice, 250 parts of pseudo-ginseng, 200 parts of Folium Apocyni Veneti, ginkgo
750 parts of leaf, 750 parts of the root of kudzu vine.
Further, the water extract powder of agaric, longan and matrimony vine is also included in the health products.
On the other hand, the present invention provides a kind of application of the health products, it is characterised in that the health products are applied to control
Treat angiocardiopathy.
It should be noted that, although the present invention is to be the theme that the content of the patent application is described with health products,
It will be appreciated by those skilled in the art that health products mentioned herein can both refer to said in ordinary meaning be used for protect
The product of strong health, and Chinese herbal product or medicine can also be referred to.
In addition, the formula and improvement formula on this basis of the present invention, by the name of the Fang Xinxin capsule in subsequently with side
Justice is launched, and any use to the formula is required to obtain the permission of Beijing Fang Zhongfang Science and Technology Ltd.s.
In addition, it is necessary to explanation, although defining the quality of each raw material in claims, art technology
Personnel are it should be understood that the composition of each raw material can be increased or decreased with equal proportion.
The effect of the health products of the present invention：
The present invention is from red yeast rice, pseudo-ginseng, Folium Apocyni Veneti, ginkgo leaf, the root of kudzu vine as raw material, and each material combination, hit high blood
Fat disease is insufficiency of the spleen and loses strong fortune, liver depression knot and hot, the uncomfortable interpretation of the cause, onset and process of an illness of qi depression to blood stasis, spleen liver, plays invigorating the spleen for eliminating dampness, promoting blood circulation and removing blood stasis, clear altogether
Liver, the effect of spleen and liver is mended, reach the healthcare function of auxiliary reducing blood lipid.
Product of the invention takes into account " release vasopasm, thrombolysis row fat, repair damaged blood vessels " three aspects, synchronously
Hand, it is main idea with " steady network work arteries and veins, dissolving stasis row is turbid, invigorates blood circulation raw new ", the blood vessel that can fundamentally solve initiation cardiovascular and cerebrovascular diseases
Lesion.
Brief description of the drawings
Fig. 1 is the preparation flow schematic diagram according to the health products of one embodiment of the invention.
Embodiment
Embodiment one
In the present embodiment, preparing uses raw material as follows：
Table 1
Before medicine preparation, it is necessary first to above-mentioned material is cleaned, sterilized.The selection of each material meets state
Family's relevant criterion.
It is prepared by medicinal powder
1st, the alcohol extracting of pseudo-ginseng, Folium Apocyni Veneti, ginkgo leaf, the root of kudzu vine
By, with pseudo-ginseng, Folium Apocyni Veneti, ginkgo leaf, the root of kudzu vine is measured, cleaning, be placed in positive cone extractor, Ran Houjia in table 1
70% ethanol for entering 8 times of amounts is extracted, and is extracted 2 hours so that the active principle in above-mentioned material is dissolved in solution.Then,
Gained mixture is filtered, obtains first alcohol extract.Add 70% second of 8 times of amounts again in the medicinal material obtained by filtering
Alcoholic solution, filtering is carried out to gained mixture and obtains second batch alcohol extract.
The alcohol extract obtained twice is mixed and is placed in vacuum concentration pot, is concentrated under reduced pressure into relative density as 1.20
~1.25 (60 DEG C of measure) (concentration conditions：55~65 DEG C, 0.08Mpa), obtain corresponding thick medicinal extract.Gained thick medicinal extract is carried out
It is dried in vacuo (technological parameter：Temperature is 70~80 DEG C, vacuum 0.08Mpa), obtain dry extract.Then dry extract is crushed,
80 mesh sieves are crossed, obtain extract extract powder.
Next, taking red yeast rice 135g, red yeast rice is carried out60Co irradiates (5KGy) sterilization processing.Will be red after sterilization processing
Starter powder is broken, and red yeast rice powder is crossed into 80 mesh sieves, obtains Hongqu powder (red colouring agent).
Then, extract extract powder and Hongqu powder (red colouring agent) are mixed, adds starch 30g and magnesium stearate 3g, be subsequently placed in motion
In mixer, mix 30 minutes.Until mixed powder color and luster is consistent, no color differnece, after being well mixed mixed powder.Take out mixed powder,
It is filled into capsule, 0.45g medicinal powder is added in each capsule.Capsule is bottled, every bottle of 60 capsules.Then, to installing
The medicine bottle of capsule is packaged, and forms product, after quality testing is qualified, storage storage.
Validity check
In order to verify the effect of Chinese herbal product prepared in the present embodiment, applicant carries out animal reality using SD rats
Test.
Specifically, first, prepare 200 male rats, fed respectively with high lipid food, feeding environment is selected in temperature
Spend 20-25 degree, humidity 40-70%RH.After two weeks is fed, from this 200 rats, body weight 150-180g, blood are selected
Clear total cholesterol level is in more than 2.2mmol/L, male rat 60 of the serum triglyceride content in more than 1.8mmol/L.
This 60 rats are divided into two groups, every group 30, ensure the mean cholesterol content of two groups of rats and average triglyceride
Content is of substantially equal.
Two groups of rats respectively as tested group and control group, then respectively the high lipid food to two groups of feeding rats 1/3 and
2/3 chow diet.Only for the rat in tested group, 0.1g medicinal powder of the invention is additionally given daily, adheres to feeding
After two weeks, blood drawing checks again for the serum triglyceride and cholesterol level of two groups of rats.
By zoopery above it can be found that the product of the present invention can substantially reduce in animal body triglycerides and
The content of cholesterol.
In addition, after zoopery has been carried out, applicant of the present invention is before its product is released, also to a large amount of painstaking effort
Pipe patient has carried out clinical trial.
The product of the present invention has the effect of vascular repair, thrombolysis lipid-lowering, row's bolt row's fat.But due in clinical trial
When, it is not easy quantitative evaluation, present invention production for the influence in terms of the vascular repair of patient, thrombolysis lipid-lowering, row's bolt row's fat after medication
The clinical trial of product is mainly tested in terms of the reduction from patients with lipid, the reduction of blood pressure and patient's readme body-feeling.
Specifically, after it have chosen 50 hypertension and vascular complication patient, blood pressure, blood fat to these patients
Measure, and record description of the patient to itself symptom.Then, after secrecy and liability clause is appointed, this 50 are given
Patient according to dosage takes the product of the present invention.When taking two weeks and one month, blood pressure, blood fat are measured again, and remember
Record description of the patient to self-condition.By the measurement to patients' blood and blood fat, find the blood pressure of patient and blood fat have it is bright
Aobvious to reduce, most of patient blood pressure and blood fat value after taking one month be able to can partly return close to the upper limit of normal value
To normal value.And also it is relieved according to the description of patient, the symptom of its each side.For example have the patient of numbness in hands and feet,
Mostly after a period of time is taken, symptom will be relieved.
Embodiment two
In the present embodiment, using the preparation method similar with embodiment one, it simply have adjusted the proportioning of raw material.At this
In embodiment, used raw material proportioning is as follows：
Table 3
Corresponding medicine is prepared based on the raw material proportioning in table 3 using with method essentially identical in embodiment one, applicant
Powder.
Similarly, the product produced for the formula, applicant are also tested, and experimental method is essentially identical.Through
It is demonstrated experimentally that the product of the dose ratio, or even it is more preferable than the dose ratio effect of embodiment one.
Embodiment three
In the present embodiment, embodiment two is further improved, in the present embodiment, raw material proportioning is as follows：
Table 4
In the present embodiment, still according to shown in Fig. 1 the step of carry out product preparation, simply medicine mixing before,
Add agaric, longan, white fungus, the water extract of matrimony vine.The water extraction of agaric, longan, white fungus, matrimony vine uses 80-100 degrees Celsius of water
Temperature, extract, then by product drying, the crushing after extraction, be mixed into medicinal powder, uniformly mixing at twice.
The present embodiment adds the extract of food composition in formula, and cost is cheaper, health environment-friendly, also, wood
Contain Auricularia polysaccharide in ear, there is the effect of reducing blood fat.Its active ingredient can preferably be obtained using water extraction.Agaric, osmanthus
Circle, white fungus, matrimony vine cooperate more gently with the five kinds of Chinese medicine added before, more preferable to the repairing effect of blood vessel, for taste
Cold of insufficiency type patient can also take.
It should be noted that, although the present invention is described in detail above in conjunction with specific embodiments and the drawings, but
It is that above description only schematically illustrates, in order to those skilled in the art's the understanding of the present invention, shown in figure
The detail of part is not the restriction to invention protection domain.Those skilled in the art it should also be understood that above-described embodiment also only
Only it is the explanation to the exemplary implementation of the present invention, not limiting the scope of the invention.
Claims (5)
1. a kind of preparation technology for the health products for reducing cholesterol, it is characterised in that it comprises the following steps：
1) pseudo-ginseng 150-320 parts, Folium Apocyni Veneti 130-270 parts, ginkgo leaf 600-850 parts, root of kudzu vine 650-900 parts, are prepared respectively,
By weight；
2), the Chinese medicine prepared in step 1) is added in extractor, and ethanol solution is added in the extractor；
3), in the extractor is carried out to the Chinese medicine prepared the alcohol extracting scheduled time；
4), the mixture in the extractor is filtered, discards the dregs of a decoction, obtains alcohol extract；
5), the alcohol extract be concentrated under reduced pressure and obtain corresponding thick medicinal extract, and reclaim ethanol；Used concentration condition
For：55~65 DEG C of temperature, vacuum 0.08MPa；And the alcohol extract is concentrated into relative density as 1.20~1.25；
6), the thick medicinal extract is dried in vacuo, obtains dry extract；
7), the dry extract is crushed and sieved, obtains extract extract powder；
8) red yeast rice 85-170 parts, are prepared, and the red yeast rice to being prepared passes through60Co radiation sterilizings；
9), the red yeast rice through sterilization processing is crushed, obtains red yeast rice powder；
10), the red yeast rice powder is well mixed with the extract extract powder, obtains the medicinal powder of the health product；
11) quantitative separating, is carried out to the medicinal powder.
2. the preparation technology of the health products according to claim 1 for reducing cholesterol, it is characterised in that the preparation technology
It is additionally included in the dry extract and adds starch 8-25 parts and magnesium stearate 1.8-3.5 parts.
3. the preparation technology of the health products according to claim 1 for reducing cholesterol, it is characterised in that the use of the red yeast rice
Measure for 135 parts, 250 parts of pseudo-ginseng, 200 parts of Folium Apocyni Veneti, 750 parts of ginkgo leaf, 750 parts of the root of kudzu vine.
4. a kind of health products for reducing cholesterol, the health products are by pseudo-ginseng 150-320 parts, Folium Apocyni Veneti 130-270 parts, ginkgo
Leaf 600-850 parts, root of kudzu vine 650-900 parts, red yeast rice 85-170 parts, or pseudo-ginseng 150-320 parts, Folium Apocyni Veneti 130-270 parts, silver
Apricot leaf 600-850 parts, the extract of root of kudzu vine 650-900 parts, red yeast rice 85-170 parts are prepared, and its preparation technology includes following step
Suddenly：
1) pseudo-ginseng 150-320 parts, Folium Apocyni Veneti 130-270 parts, ginkgo leaf 600-850 parts, root of kudzu vine 650-900 parts, are prepared respectively,
By weight；
2), the Chinese medicine prepared in step 1) is added in extractor, and ethanol solution is added in the extractor；
3), in the extractor is carried out to the Chinese medicine prepared the alcohol extracting scheduled time；
4), the mixture in the extractor is filtered, discards the dregs of a decoction, obtains alcohol extract；
5), the alcohol extract be concentrated under reduced pressure and obtain corresponding thick medicinal extract, and reclaim ethanol；Used concentration condition
For：55~65 DEG C of temperature, vacuum 0.08MPa；And the alcohol extract is concentrated into relative density as 1.20~1.25；
6), the thick medicinal extract is dried in vacuo, obtains dry extract；
7), the dry extract is crushed and sieved, obtains extract extract powder；
8) red yeast rice 85-170 parts, are prepared, and the red yeast rice to being prepared passes through60Co radiation sterilizings；
9), the red yeast rice through sterilization processing is crushed, obtains red yeast rice powder；
10), the red yeast rice powder is well mixed with the extract extract powder, obtains the medicinal powder of the health product；
11) quantitative separating, is carried out to the medicinal powder.
5. the health products according to claim 4 for reducing cholesterol, it is characterised in that the dosage of raw material each by mass is
135 parts of red yeast rice, 250 parts of pseudo-ginseng, 200 parts of Folium Apocyni Veneti, 750 parts of ginkgo leaf, 750 parts of the root of kudzu vine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510063794.0A CN104585767B (en) | 2015-02-06 | 2015-02-06 | A kind of health products and preparation technology for reducing blood fat |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510063794.0A CN104585767B (en) | 2015-02-06 | 2015-02-06 | A kind of health products and preparation technology for reducing blood fat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104585767A CN104585767A (en) | 2015-05-06 |
| CN104585767B true CN104585767B (en) | 2018-03-06 |
Family
ID=53112101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510063794.0A Active CN104585767B (en) | 2015-02-06 | 2015-02-06 | A kind of health products and preparation technology for reducing blood fat |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104585767B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113499414A (en) * | 2021-08-27 | 2021-10-15 | 威海德尚医中医药科技有限公司 | A Chinese medicinal composition for thrombolysis and preventing cardiovascular diseases, and its preparation method |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101624563A (en) * | 2009-07-28 | 2010-01-13 | 崔凤玉 | Preparation method of hypolipidemic health care vinegar |
| CN102973821A (en) * | 2012-08-21 | 2013-03-20 | 苏州谷力生物科技有限公司 | Composition having vascular headache improvement effect |
| CN103735603B (en) * | 2014-02-11 | 2016-08-31 | 武汉市元大生物科技有限公司 | A kind of compound antihyperglycemic soft capsule and preparation method thereof |
| CN103829238B (en) * | 2014-02-17 | 2015-07-29 | 大连圣弘医药有限公司 | Health food of a kind of reducing blood lipid and preparation method thereof |
| CN103828983A (en) * | 2014-02-23 | 2014-06-04 | 廖洋镱 | Health-care eucommia bark tea |
-
2015
- 2015-02-06 CN CN201510063794.0A patent/CN104585767B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104585767A (en) | 2015-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102159227B (en) | Pharmaceutical composition for purifing vein and preparation method thereof | |
| CN103494998A (en) | Aloe vera extract, method of producing aloe vera extract, and hyperglycemia improving agent | |
| CN108926702A (en) | A kind of Chinese herbal medicine formula and preparation method thereof for conditioning subhealth state | |
| CN109700011A (en) | A kind of health food and preparation method thereof improving sleep | |
| CN105727145A (en) | Traditional Chinese medicine drug for treating spleen deficiency phlegm-dampness syndrome type hyperlipidaemia | |
| CN105920439A (en) | Effective part composition containing corn stigma extract and preparation method and application of effective part composition | |
| CN102697843B (en) | Health care product for cleaning colon and promoting defecation, and eliminating toxin and beautifying skin and preparation method of same | |
| CN104585767B (en) | A kind of health products and preparation technology for reducing blood fat | |
| CN106176952A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja and Folium Ilicis | |
| CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
| CN106262825A (en) | A kind of cardiovascular vegetable health-care formula capsule and preparation method thereof | |
| CN104906190A (en) | Antler powder wine and preparation method thereof | |
| AU2012325600B2 (en) | Pharmaceutical composition regulating blood fat and preparation process thereof | |
| WO2019100843A1 (en) | Enteromorpha prolifera polysaccharide composite blood lipid-lowering health care product and preparation method therefor | |
| KR101067959B1 (en) | The method of fermented oil composite effectively to cure and prevent the cold and flu | |
| CN104288566B (en) | Traditional Chinese medicine composition for reducing cholesterol and/or reducing blood lipids as well as preparation method and application of traditional Chinese medicine composition | |
| CN1115159C (en) | Red sage containing medicine composition and its preparation and use | |
| CN1660207A (en) | Preparation of health care for reducing blood fat and cholesterol, and producing method | |
| CN106177476A (en) | A kind of Hyperglycemic health care compositions comprising Herba Dendrobii and Pericarpium Citri Reticulatae | |
| CN104606571A (en) | Fresh spinach root tea substituted drink with effects of helping produce saliva and slaking thirst and preparation method thereof | |
| CN103316217A (en) | Traditional Chinese medicine preparation for treating heart diseases and preparation method therefor | |
| CN103623189B (en) | A kind of Chinese traditional compound medicine and preparation method thereof of recession and reversal of atherosclerosis patch | |
| CN107137651A (en) | It is a kind of to treat medicine of depression and preparation method thereof | |
| CN104095913B (en) | One kind plays both sides of the street pharmaceutical composition and preparation method thereof | |
| CN107854588A (en) | A kind of Chinese medicine composition for treating fatty liver and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |